Patent ID: 9649311
Date: 2017-05-16
CPC Classifications: A61K,A61P

Claim:
1. A compressed tablet for oral administration, which comprises: (A) an intragranular component comprising: (B) an extragranular component comprising: wherein: (A)(i) the potassium salt of raltegravir is employed on a free phenol basis in an amount of at least about 30 wt. %; (A)(ii) the first superdisintegrant is employed in an amount in a range of from 3 wt. % to about 12 wt. %; (A)(iii) the binder is employed in an amount in a range of from about 0.5 wt. % to about 7 wt. %; (B)(i) the second superdisintegrant is employed in an amount in a range of from about 3 wt. % to about 20 wt. %; (B)(ii) the filler is employed in an amount in a range of from about 10 wt. % to about 40 wt. %; and (B)(iii) the lubricant is employed in an amount in a range of from about 0.5 wt. % to about 2.5 wt. %; wherein the total amount of superdisintegrant is in a range of from about 6 wt. % to about 20 wt. %; and wherein the weight percent of each ingredient in the compressed tablet is based on the total weight of the compressed tablet.